Bevacizumab

Vedolizumab is an anti-α4β7 integrin mAb for ulcerative colitis and Crohn's disease. Its gut-selective anti-lymphocyte trafficking mechanism avoids systemic immunosuppression and PML risk, making it the preferred safety option among IBD biologics.

Abaloparatide is a PTHrP(1-34) analog acting as an agonist at the PTH1 receptor (PTH1R). It activates the cAMP signaling pathway to stimulate osteoblastic activity and new bone formation. Administered as 80 mcg subcutaneously once daily. Abaloparatide demonstrates rapid and robust bone formation with the b...

Aflibercept is a VEGF trap fusion protein targeting VEGF-A, VEGF-B, and PIGF. As the second-largest anti-VEGF ophthalmology blockbuster, its extended q8w+ dosing in DME significantly reduces injection burden, with a mature biosimilar competitive landscape.

Amphotericin B is a true single bilayer liposomal drug delivery system with amphotericin B intercalated within a liposomal membrane composed of hydrogenated soy phosphatidylcholine, distearoyl phosphatidylglycerol, and cholesterol. Liposomes are less than 100 nm in diameter. The liposomal encapsulation per...

Aprepitant, a highly selective neurokinin-1 receptor antagonist, provides superior protection against both acute and delayed chemotherapy-induced nausea and vomiting compared to conventional antiemetic agents, with a single dose offering sustained efficacy over many hours. Its ability to be combined with 5...

Atezolizumab is an anti-PD-L1 mAb and the first approved for NSCLC first-line immunotherapy combinations. With differentiated positioning in urothelial carcinoma and HCC (combined with bevacizumab), it remains a significant competitor in the PD-L1 landscape.

Bupivacaine utilizes proprietary DepoFoam technology to encapsulate bupivacaine within multivesicular liposomes, enabling sustained analgesia for up to 72 hours through a unique tri-phasic release mechanism involving initial burst, membrane diffusion, and particle erosion. This prolonged duration of action...

Daratumumab is an anti-CD38 mAb for multiple myeloma across all lines of therapy. From first-line to relapsed settings, its subcutaneous Faspro formulation compresses infusion from hours to minutes, making it the absolute cornerstone of MM treatment.

Denosumab is a human anti-RANKL mAb; Prolia for osteoporosis and Xgeva for bone metastases. Its semiannual subcutaneous dosing offers superior compliance vs oral bisphosphonates, with dual-market positioning across orthopedics and oncology.

Durvalumab is an anti-PD-L1 mAb and the standard PACIFIC consolidation therapy for unresectable Stage III NSCLC post-chemoradiation. As the sole immunotherapy for limited-stage SCLC, its precise positioning in radiation-immunotherapy combinations sets the benchmark for locally advanced tumor care.

Faricimab is the world's first bispecific antibody for ophthalmology, targeting both Ang-2 and VEGF-A. Enabling q16w dosing in DME/wAMD, it delivers a revolutionary compliance breakthrough and represents the next-generation blockbuster in retina.

Ipratropium Bromide and Salbutamol is a combination of ipratropium bromide (anticholinergic) and albuterol sulfate (beta2-adrenergic agonist) delivered via the soft mist inhaler. It provides superior relief of bronchospasm compared to either agent alone in COPD patients with persistent symptoms despite reg...

Q

Up to now, 

d

Up to now, there are a

There are